- Ocular Pain, a $10+ billion global market, with significant unmet medical need
- License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies
IRVINE, Calif., PARIS, France, and HONG KONG, China, January 7, 2021 – IACTA Pharmaceuticals, Inc. (“IACTA”) and Pharmaleads, with Pharmaleads Greater China, today announced they have entered into licensing agreements, with IACTA acquiring global rights to Pharmaleads’ Dual Enkephalinase Inhibitors (DENKI®), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain.
“With this agreement, IACTA and Pharmaleads will collaborate to develop next-generation pain treatments to help the millions of people across the globe living with the debilitating effects of ocular pain,” said Damon Burrows, CEO of IACTA. “We believe that the epithelial protective properties of DENKI observed in preclinical studies, combined with its pain-relieving properties will revolutionize eye care.”
“Today’s announcement further exemplifies IACTA’s business momentum, as we continue to foster research and development initiatives to address unmet medical needs in the global eye care market,” continued Damon Burrows.
